nach oben

International Journal of Hematology

Erschienen in:

01.05.2011 | Case Report

Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant

verfasst von: Yuval Tal, Guy Haber, Matan J. Cohen, Micci Phillips, Gail Amir, Dina Ben-Yehuda, Arie Ben-Yehuda

Erschienen in: International Journal of Hematology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

We present a case of a 52-year-old male who was evaluated due to anorexia, persistent diarrhea, weight loss, and liver enzyme elevations, with no hematologic laboratory abnormalities. Imaging modalities revealed several tissue lesions involving the pancreas, the right kidney, and an axillary lymph node. Diagnosis of Castleman disease was reached only due to the tissue obtained from the lymph node. Chemotherapy and immunosuppression led to a short remission. The patient underwent autologous stem cell transplantation, and has since been in remission. This case demonstrates the cryptogenic and chameleon-like nature of Castleman disease. Challenges in treating Castleman disease patients reflect current limitations and the need for a greater understanding of disease pathogenesis.

Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250(23):1001–5.CrossRefPubMed

Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43(8):698–704.CrossRefPubMed

Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–6.CrossRefPubMed

Klein WM, Rencic A, Munshi NC, Nousari CH. Multicentric plasma cell variant of Castleman’s disease with cutaneous involvement. J Cutan Pathol. 2004;31(6):448–52.CrossRefPubMed

Miltenyi Z, Toth J, Gonda A, Tar I, Remenyik E, Illes A. Successful immunomodulatory therapy in Castleman disease with paraneoplastic Pemphigus Vulgaris. Pathol Oncol Res. 2008.

Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128(8):657–62.CrossRefPubMed

Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003;82(12):766–8.CrossRefPubMed

Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol. 2005;78(4):302–5.CrossRefPubMed

Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.CrossRefPubMed

10.

van Rhee F, Alikhan M, Munshi N, et al. Anti-IL6 antibody (ab) based strategies improve the management of HIV negative Castleman’s disease. Blood. 2004;104:897a.

11.

Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease. Haematologica. 2007;92(6):857–8.CrossRefPubMed

12.

Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32.CrossRefPubMed

13.

Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95(1):56–61.PubMed

14.

Advani R, Warnke R, Rosenberg S. Treatment of multicentric Castleman’s disease complicated by the development of non-Hodgkin’s lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. Ann Oncol. 1999;10(10):1207–9.CrossRefPubMed

15.

Ogita M, Hoshino J, Sogawa Y, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68(3):171–6.CrossRefPubMed

16.

Repetto L, Jaiprakash MP, Selby PJ, Gusterson BA, Williams HJ, McElwain TJ. Aggressive angiofollicular lymph node hyperplasia (Castleman’s disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol. 1986;4(3):213–7.CrossRefPubMed

17.

Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004;104(10):3400–7.CrossRefPubMed

18.

Ganti AK, Pipinos I, Culcea E, Armitage JO, Tarantolo S. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol. 2005;79(3):206–10.CrossRefPubMed

19.

Halac M, Ergul N, Sager S, Demir A, Buyukpinarbasli N, Sonmezoglu K. PET/CT findings in a multicentric form of Castleman’s disease. Hell J Nucl Med. 2007;10(3):172–4.PubMed

20.

Iagaru A, Mari C, Sam Gambhir S. Follicular dendritic sarcoma within a focus of Castleman’s disease. Serial FDG PET/CT in the follow up of recurrence with histopathologic confirmation. Rev Esp Med Nucl. 2007;26(1):40–5.CrossRefPubMed

21.

Pelosi E, Skanjeti A, Cistaro A, Arena V. Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman’s disease: a case report. J Med Case Rep. 2008;2:99.CrossRefPubMedPubMedCentral

22.

Ramos CD, Massumoto CM, Rosa MF, et al. Focal bone marrow involvement in multicentric Castleman disease demonstrated by FDG PET/CT. Clin Nucl Med. 2007;32(4):295–6.CrossRefPubMed

Titel: Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant
verfasst von: Yuval Tal
Guy Haber
Matan J. Cohen
Micci Phillips
Gail Amir
Dina Ben-Yehuda
Arie Ben-Yehuda
Publikationsdatum: 01.05.2011
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2011
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0812-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes

Rituximab for prevention and treatment of graft-versus-host disease

Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease

Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan

Guest editorial: role of monoclonal antibodies for the prevention and treatment of graft-versus-host disease

Social outcomes and quality of life of childhood cancer survivors in Japan: a cross-sectional study on marriage, education, employment and health-related QOL (SF-36)

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie